EKKDA Announces Sales-Distribution Agreement with OCuSOFT Inc.

EKKDA Research, LLC, an ophthalmic-focused research and development company based in Kingsland, Texas is pleased to announce a sales-distribution agreement has been reached with OCuSOFT Inc.

Stacy Foster, EKKDA’s Chairman and the former Chief Business Officer for OCuSOFT®, made the announcement today.

According to Mr. Foster, given the established ophthalmic relationships both in ophthalmology and optometry, EKKDA’s research projects will be focused primarily on eye care.  There are, however, other opportunities in various fields including dermatology, urology, and neurology to name a few. The greater Austin area has become a hotbed of innovation in both technology and medicine according to Mr. Foster.  He also states, “Some of the early projects EKKDA is working on will be quicker to market so having a sales, marketing, and distribution partner like OCuSOFT® is a real plus. They have the respect of the eye care community with a long track record of service. I should know I spent 11 years with the company”.  Mr. Foster goes on to say that further announcements relating to projects underway will be made in due course.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”